WO2000042183A3 - Marqueur tumoral zsig62 - Google Patents

Marqueur tumoral zsig62 Download PDF

Info

Publication number
WO2000042183A3
WO2000042183A3 PCT/US2000/001902 US0001902W WO0042183A3 WO 2000042183 A3 WO2000042183 A3 WO 2000042183A3 US 0001902 W US0001902 W US 0001902W WO 0042183 A3 WO0042183 A3 WO 0042183A3
Authority
WO
WIPO (PCT)
Prior art keywords
zsig62
tumor suppressor
gene
mutations
suppressor genes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/001902
Other languages
English (en)
Other versions
WO2000042183A2 (fr
Inventor
Paul O Sheppard
Julia E Novak
Fenella C Raymond
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zymogenetics Inc
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Priority to CA002371752A priority Critical patent/CA2371752A1/fr
Priority to AU33507/00A priority patent/AU3350700A/en
Publication of WO2000042183A2 publication Critical patent/WO2000042183A2/fr
Anticipated expiration legal-status Critical
Publication of WO2000042183A3 publication Critical patent/WO2000042183A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Des études ont démontré que les mutations de gènes suppresseurs de tumeurs se produisent à un stade précoce du processus de carcinogenèse, et que ces mutations sont corrélées à un développement ultérieur du cancer. La détection de telles modifications devrait permettre de disposer de marqueurs moléculaires utiles au diagnostic, à la surveillance, à l'identification et à l'intervention à un stade précoce et à l'établissement d'un pronostic. Un nouveau gène humain, dénommé 'Zsig62', est localisé dans une région du chromosome 16q qui est associée au cancer du sein et de la prostate, et qui semble contenir des gènes suppresseurs de tumeurs. De même qu'un gène suppresseur de tumeur, le gène Zsig62 est exprimé dans des tissus normaux particuliers mais pas dans les tumeurs dérivées de ces tissus.
PCT/US2000/001902 1999-01-19 2000-01-18 Marqueur tumoral zsig62 Ceased WO2000042183A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA002371752A CA2371752A1 (fr) 1999-01-19 2000-01-18 Marqueur tumoral zsig62
AU33507/00A AU3350700A (en) 1999-01-19 2000-01-18 Tumor marker zsig62

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23361099A 1999-01-19 1999-01-19
US09/233,610 1999-01-19

Publications (2)

Publication Number Publication Date
WO2000042183A2 WO2000042183A2 (fr) 2000-07-20
WO2000042183A3 true WO2000042183A3 (fr) 2003-05-08

Family

ID=22877973

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/001902 Ceased WO2000042183A2 (fr) 1999-01-19 2000-01-18 Marqueur tumoral zsig62

Country Status (3)

Country Link
AU (1) AU3350700A (fr)
CA (1) CA2371752A1 (fr)
WO (1) WO2000042183A2 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992021754A1 (fr) * 1991-06-07 1992-12-10 Osaka Bioscience Institute Adn qui code pour le recepteur de la secretine et polypeptide pour lequel code cet adn
WO1999053095A2 (fr) * 1998-04-09 1999-10-21 Whitehead Institute For Biomedical Research Marqueurs bialleliques
WO2000037677A1 (fr) * 1998-12-22 2000-06-29 Imperial Cancer Research Technology Limited Cancer en rapport avec un gene suppresseur de tumeur du chromosome humain 16q

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992021754A1 (fr) * 1991-06-07 1992-12-10 Osaka Bioscience Institute Adn qui code pour le recepteur de la secretine et polypeptide pour lequel code cet adn
WO1999053095A2 (fr) * 1998-04-09 1999-10-21 Whitehead Institute For Biomedical Research Marqueurs bialleliques
WO2000037677A1 (fr) * 1998-12-22 2000-06-29 Imperial Cancer Research Technology Limited Cancer en rapport avec un gene suppresseur de tumeur du chromosome humain 16q

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
CHEN T ET AL: "Deletion map of chromosome 16q in ductal carcinoma in situ of the breast: refining a putative tumor suppressor gene region", CANCER RESEARCH, vol. 56, 1996, pages 5605 - 5609, XP002136829 *
DATABASE EMBL NUCLEOTIDE AND PROTEIN SEQUENCES, 15 July 1999 (1999-07-15), HINXTON, GB, XP002147258 *
DATABASE WPI Section Ch Week 199252, Derwent World Patents Index; Class B04, AN 1992-433652, XP002147259 *
ELO J P ET AL: "Three independently deleted regions at chromosome arm 16q in human prostate cancer: Allelic loss at 16q24.1-q24.2 is associated with aggressive behaviour of the disease, recurrent growth, poor differentiation of the tumour and poor prognosis for the patient.", BRITISH JOURNAL OF CANCER, vol. 79, no. 1, January 1999 (1999-01-01), pages 156 - 160, XP000925910, ISSN: 0007-0920 *
ELO JUSSI P ET AL: "Loss of heterozygosity at 16q24.1-q24.2 is significantly associated with metastatic and aggressive behavior of prostate cancer.", CANCER RESEARCH, vol. 57, no. 16, 1997, pages 3356 - 3359, XP000925961, ISSN: 0008-5472 *
KAWAKAMI MASAKO ET AL: "Involvement of H-cadherin (CDH13) on 16q in the region of frequent deletion in ovarian cancer.", INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 15, no. 4, October 1999 (1999-10-01), pages 715 - 720, XP000925920, ISSN: 1019-6439 *
LATIL A ET AL: "Loss of heterozygosity at chromosome 16q in prostate adenocarcinoma:identification of thre independent regions", CANCER RESEARCH, vol. 57, 15 March 1997 (1997-03-15), pages 1058 - 1062, XP002136828 *
SCHMUTZLER R K ET AL: "ASSOCIATION OF ALLELIC LOSSES ON HUMAN CHROMOSOMAL ARMS 11Q AND 16Q IN SPORADIC BREAST CANCER", INTERNATIONAL JOURNAL OF CANCER,US,NEW YORK, NY, vol. 69, no. 4, 22 August 1996 (1996-08-22), pages 307 - 311, XP000791171, ISSN: 0020-7136 *
WHITMORE SCOTT A ET AL: "Construction of a high-resolution physical and transcription map of chromosome 16q24.3: A region of frequent loss of heterozygosity in sporadic breast cancer.", GENOMICS, vol. 50, no. 1, 15 May 1998 (1998-05-15), pages 1 - 8, XP000925915, ISSN: 0888-7543 *

Also Published As

Publication number Publication date
CA2371752A1 (fr) 2000-07-20
AU3350700A (en) 2000-08-01
WO2000042183A2 (fr) 2000-07-20

Similar Documents

Publication Publication Date Title
Cooney et al. Distinct regions of allelic loss on 13q in prostate cancer
Schwartz Cutaneous metastatic disease
Menke et al. The Wilms' tumor 1 gene: oncogene or tumor suppressor gene?
Sakorafas et al. Molecular biology of pancreatic cancer; oncogenes, tumour suppressor genes, growth factors, and their receptors from a clinical perspective
WO1997033551A3 (fr) Compositions et procedes de diagnostic, de prevention et de traitement de la croissance et de la proliferation de cellules neoplasiques
EP1522594A3 (fr) Methode et trousses pour evaluer un cancer
Wright et al. Frequent loss of heterozygosity and three critical regions on the short arm of chromosome 8 in ovarian adenocarcinomas
EP2261369A3 (fr) Profilage de l'expression génétique dans des tissus de tumeurs prélevées par biopsie
WO1998010069A3 (fr) Proteine e25a, ses procedes de production et d'utilisation
WO2002092854A3 (fr) Genes exprimes dans le cancer du sein en tant que cibles therapeutique et de pronostic
WO1999035170A8 (fr) Compositions et methodes pour le traitement des tumeurs
WO2002044331A3 (fr) Dap-kinase et hoxa9, deux genes humains associes a la genese, a la progression et a l'agressivite du cancer du poumon non a petites cellules
WO1999014327A3 (fr) Genes amplifies dans des tumeurs, anticorps diriges contre les proteines codees par ces genes, et leur utilisation dans le diagnostic et le traitement du cancer
WO2002081749A3 (fr) Sequences d'adn a methylation modifiee utilisees comme marqueurs associes au cancer humain
WO2000055629A3 (fr) Nouvelles techniques permettant de traiter et de diagnostiquer le cancer du sein, compositions et techniques de criblage pour modulateurs de cancer du sein
WO2003032813A3 (fr) Methodes de traitement du carcinome
WO2001009189A3 (fr) Compositions et procedes de traitement de tumeurs
WO2007006408A3 (fr) Methodes et kits de prevision et de surveillance d'une reponse directe a une therapie anti-cancereuse
AU2001290949A1 (en) Id-1 and id-2 genes and products as diagnostic and prognostic markers and therapeutic targets for treatment of breast cancer and other types of carcinoma
WO2002012285A3 (fr) Suppresseur de tumeur car-1
AU6583700A (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
Herbst et al. Identification of two distinct deletion targets at 11q23 in cutaneous malignant melanoma
WO2005119260A3 (fr) Methodes de prediction et de surveillance de reponse au traitement du cancer
WO2004075835A3 (fr) Procédés de traitement de carcinome
WO2000015666A3 (fr) Compositions et methodes de traitement des tumeurs

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2371752

Country of ref document: CA

Ref country code: CA

Ref document number: 2371752

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/007331

Country of ref document: MX

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase